🇺🇸

Index Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — April 29, 2026

Across 50 SEC filings primarily from financials, insurers, and select S&P 500 Healthcare names like Humana, Biogen, and Regeneron (despite broader scope), Q1 2026 results show robust revenue growth averaging +15-20% YoY in reporting firms (e.g., Regeneron +19%, Humana +23.5%, Tradeweb +21%), but mixed profitability with net income/EPS declines in 60% of cases due to higher provisions, R&D, and costs (e.g., Humana EPS -4.6% YoY, Regeneron NI -10%). Healthcare highlights include product growth (Biogen LEQEMBI +74% YoY, Regeneron Dupixent +33%) offset by legacy declines (Biogen SPINRAZA -12%), with M&A activity (Biogen-Apellis, Woori-Tongyang) signaling consolidation. Capital returns strong via buybacks (Regeneron $3B auth., multiple banks repurchasing) and dividends (e.g., Coastal $0.29 Q2), but credit risks emerge in banks (NPAs up in Citizens, Coastal provisions +$3.4M QoQ). Sentiment mixed/neutral in 70% filings, with positive M&A/earnings beats countered by guidance cuts (Humana GAAP EPS to $8.36 from $8.89). Portfolio trend: financials outperform healthcare on NIM stability (avg 3.5-3.7%), but healthcare catalysts like approvals (Regeneron EYLEA HD, Otarmeni) offer upside. Implications: favor growth biotechs over payers amid margin pressures; monitor bank credit provisions for sector spillovers.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 28, 2026

Across 27 filings in the USA S&P 500 Technology intelligence stream, a dominant theme emerges from multiple 13F-HR disclosures showing overwhelming institutional conviction in core tech names like Nvidia, Broadcom, Apple, Amazon, and Alphabet, with top holdings exceeding $1B in several portfolios and tech/semicon comprising 20-40% of allocations. Non-tech filings reveal mixed results: REITs like AvalonBay posted 40% YoY EPS growth but FFO declines and expense inflation, while banks such as Camden National surged 200% YoY net income amid deposit growth yet faced QoQ NIM compression of 5 bps. Forward-looking catalysts cluster in May 2026 (SPAC merger vote/close) and EOY 2026 (biotech trial data), with capital returns strong via $198M AvalonBay buybacks and Camden repurchases/dividends. Tech-specific signals include director departures at Intuit and Ribbon Communications (high risk), Knowles 10-Q metrics pending deeper review, and institutional passives overweighting growth tech/ETFs. Portfolio-level trends highlight tech resilience amid broader sector volatility, with 5/7 detailed earnings showing YoY beats but QoQ softening (avg net income -3% linked quarter). Actionable now: overweight tech on institutional flows, monitor SPAC redemptions and REIT guidance tweaks for relative outperformance.

11 high priority 16 medium 27 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 28, 2026

Across 37 SEC filings from NASDAQ-100 constituents and related entities on April 28, 2026, dominant themes include mixed Q1 2026 results for REITs and regional banks—strong YoY EPS growth (AvalonBay +40.4%, Camden National +200%) offset by QoQ declines, margin compression (NIM -5 bps, op ex +4.7%), and elevated expenses—amid ongoing developments and capital returns. Biotech/pharma shines with Immunic's CMO appointment advancing phase 3 MS trials (data E2026) and Gilead's $7.1B Arcellx acquisition completion (77.2% tendered at $115/share + CVR). SPAC activity peaks with AParadise merger deadlines (Apr 29 non-redemption, May 1 vote, May 7 close), while 13F filings reveal institutional tech overweight (e.g., Fukoku's $195M Broadcom, National Mutual's $89M Nvidia). Capital allocation favors buybacks (AvalonBay $198M, Camden 33k shares) and dividends, with REIT Net Debt/EBITDA ~4.8x and bank CET1 >12%. Portfolio trends flag REIT NOI stagnation (AvalonBay +0.2%), bank deposit growth (Camden +1% QoQ), and M&A upside (Arcellx CVR to 2030). Actionable implications: Biotech catalysts for alpha, SPAC arbitrage near-term, caution on REIT expense trends and director departures (Intuit, Ribbon).

14 high priority 23 medium 37 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 28, 2026

Across 50 filings from S&P 500 Financials and related sectors on April 28, 2026, Q1 2026 earnings dominate with 20+ companies reporting average revenue growth of 12% YoY (e.g., PJT Partners +29%, Bread Financial +6% NII), but profitability mixed as 8/15 showed net losses or declines due to higher costs/fuel (e.g., JetBlue op loss -10% margin, Shutterstock -18% rev). Margin trends split: expansions in 6/12 (Bread NIM +119bps, Polaris GP +423bps) vs compressions in 5/12 (Allegion -200bps adj). Capital allocation robust with $1B+ buybacks (PJT $244M, Pentair $200M, American Tower $184M) and dividend hikes (Pentair 50th year +8%, Enterprise +2.8%). M&A catalysts abound (RE/MAX merger, Ligand/XOMA accretive, CECO/Thermon June close), with 7/10 guidances raised (Centene EPS >$3.40, Curbline OFFO $1.20-1.23). Insider conviction mixed (high ownership Lindblad 26%), 13Fs show tech-heavy tilts (China Universal NVIDIA top). Portfolio trend: Resilient growth amid costs, bullish forward outlooks signal upside for cyclicals/financials.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 28, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader cross-sector insights), key themes include modest revenue growth averaging 5-10% YoY in staples like beverages (CCEP +6.7%, KO +12%) offset by pricing/margin pressures (KMB gross margin -60bps, UPS US Domestic rev -2.3%), mixed sentiments in 60% of detailed reports, and positive volume drivers (CCEP +8.5% unit cases, KO +3%). Capital allocation favors shareholder returns with buybacks (Valmont $57.5M, Asbury $147M) and dividend hikes (First Commonwealth +3.7%), while forward guidance shows resilience (Omnicell raised FY EBITDA to $153-168M, GM raised FY EBIT to $13.5-15.5B). Outliers include strong international growth (KMB Intl Personal Care +9.1%) amid US softness, and neutral institutional 13F holdings signaling stability. Portfolio-level trends highlight margin compression in 4/7 earnings reports (avg -100bps) but operating leverage in others (Valmont op inc +21.3%), implying defensive positioning in staples amid economic uncertainty. Critical developments like KO value share gains and Omnicell 15% rev growth offer near-term catalysts, while risks from originations declines (GM Financial -15% YoY) warrant caution.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 28, 2026

Across 50 SEC filings from S&P 500 Industrials and related streams dated April 28, 2026, Q1 2026 results reveal mixed performance with transportation/industrials showing revenue resilience (e.g., ArcBest +3.2% YoY to $998.8M, Avery Dennison +7% to $2.3B) amid tonnage/shipment growth but margin pressures (ArcBest OR 97.3% vs 95.9%, UPS U.S. Domestic op profit -47% to $515M). Biotech/pharma subsets shone with guidance raises (Ligand rev to $270-310M post-XOMA acquisition, Axogen 20%+ FY growth) and catalysts (Rocket $180M PRV sale), while media/real estate faced headwinds (Shutterstock rev -18% YoY, reAlpha -9%). Capital allocation remains shareholder-friendly with $860M returns at Hilton, $133M at Avery, UPS $5.4B FY dividends; 13F filings highlight institutional tech/ETF bias (e.g., China Universal NVIDIA $81M top). Overarching themes include accretive M&A (Ligand, Real Brokerage scaling agents 5x), cost savings (UPS $600M Q1), and pending regulatory hurdles (Shutterstock-Getty CMA deadline June 14). Portfolio-level trends: 7/12 earnings reporters posted YoY rev growth averaging +10% but 5 saw op margin compression (-150bps avg); forward catalysts cluster in H2 2026 (deal closes, trials). Implications: Tactical buys in growth industrials/biotech, caution on volume-dependent transports amid softening demand.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 28, 2026

Across 16 filings in the S&P 500 Energy stream (with some cross-sector context), key themes include stable capital returns from energy leaders like Cheniere amid sparse sector-specific updates, robust Q1 growth at Sherwin-Williams despite soft end-market demand, and M&A momentum via SPAC mergers and acquisitions like Real Brokerage's RE/MAX deal. Period-over-period trends show Sherwin-Williams net sales +6.8% YoY to $5.67B and EPS +7.5% to $2.15, alongside net income +6.1% YoY in its 10-Q, but offset by declines in residential/DIY sales and negative working capital; Hallmark Venture narrowed losses but reported zero revenue for second year with massive share dilution. Cheniere Energy Partners and Inc. declared steady quarterly distributions/dividends ($0.790/unit and $0.555/share), signaling shareholder-friendly capital allocation. 13F filings reveal sustained institutional conviction in Chevron (top holding for Cherokee Insurance at $11.4M and Abel Hall), while SPAC AParadise eyes May 7 merger close. Overall sentiment mixed-positive with energy stability contrasting growth headwinds elsewhere; actionable catalysts cluster in early May for distributions and M&A votes.

7 high priority 9 medium 16 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 28, 2026

Across 50 filings for the USA Dow Jones 30 intelligence stream (period April 28, 2026), Q1 2026 earnings dominate with 18 reports showing aggregate revenue growth of +12% YoY on average (e.g., +32% Herc, +12% Coke, +10% S&P Global), but mixed profitability: 10/18 posted net income gains (avg +25% YoY) while 5 widened losses amid cost pressures (e.g., Herc net loss -33% YoY worse, Coronado production -22% QoQ). M&A activity surges with RE/MAX's $880M merger (3 filings, positive sentiment, H2 close), CECO-Thermon (June close), and SPACs like AParadise/Enhanced. Capital returns strong: 12 companies repurchased shares (e.g., $250M Zimmer, $198M AvalonBay, $1B S&P Global) and affirmed/raised dividends/guidance (e.g., UPS $5.4B FY dividends, Zimmer EPS to $8.40-8.55). Proxy filings (12) neutral with high insider ownership (e.g., 26% Lindblad) but some delinquent Section 16s; 13Fs (9) show passive ETF-heavy portfolios. Sector patterns: Industrials/Consumer resilient growth, Financials credit improving but volumes mixed; risks from coal idling (Coronado) and debt covenants (SpringBig). Actionable: Favor buyback-heavy names with raised guidance amid modest organic growth (avg 4% YoY).

15 high priority 35 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 28, 2026

Across 50 filings from the USA S&P 500 Consumer Discretionary stream (broadly including retail, auto, hotels, entertainment), Q1 2026 results show mixed performance with 12/20 key quarterly reporters posting net income growth averaging +25% YoY (e.g., Hilton +28%, Bread Financial +32%), but 8 experiencing declines or widened losses (avg -30% YoY, e.g., Hycroft Mining -310%). Revenue trends positive in consumer names (Hilton +9% YoY, CCEP +6.7% reported), but flat/declining in autos (GM -0.9% YoY) and industrial REITs (Rexford -3% YoY); NIM expanded in 5/8 financials (avg +25 bps YoY). Capital allocation favors returns with $860M shareholder payouts at Hilton, $200M buybacks at Rexford, and dividend hikes (First Commonwealth +3.7% to $0.14). Forward guidance raised at GM (FY EBIT $13.5-15.5B, +$0.5B tariff adjust) signals resilience; institutional 13Fs reveal sustained tech/consumer holdings (e.g., PFA Pension $2.2B Apple). Sector implications: Consumer discretionary resilient amid macro pressures, with hotels outperforming autos; watch liquidity in small caps and SPAC dilutions.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 28, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (including adjacent life sciences and biotech), Q1 2026 results show mixed performance with average revenue growth of 7-10% YoY in reporting healthcare firms like Centene (+5-7%) and biotechs like Wave Life Sciences (+315% to $38.2M) and BeOne Medicines (+49% BRUKINSA to $3.9B), but offset by membership declines (Centene -6% to 26.3M) and rising expenses (Wave R&D +17%). Forward-looking guidance is raised in key players (Centene FY2026 adj EPS >$3.40, premium rev $171-175B), while biotechs highlight pipeline catalysts into mid-2026. Capital allocation trends favor debt reduction (Centene -$1B) and buybacks/dividends (First Commonwealth +3.7% dividend), with neutral insider activity but leadership transitions (Stewards, BeOne). Proxy filings dominate (12/50) signaling AGM season with director elections and comp approvals (JNJ strong support, BeOne profitability milestone). Sentiment skews mixed/neutral (60%), with healthcare outliers in profitability (BeOne first GAAP profit) amid broader financial sector crossovers showing NIM expansion (avg +20-30bps). Portfolio implication: Favor managed care with raised guidance and biotechs with extended cash runways (Wave to 3Q2028), monitor membership trends and AGMs for governance risks.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 27, 2026

Across 13 filings in the USA S&P 500 Technology stream, key themes include mixed Q1 2026 earnings with revenue growth in telecom/software (e.g., Verizon +2.9% YoY revenue, Cadence Q1 results announced) offset by rising debt and provisions elsewhere, neutral 13F snapshots revealing sustained institutional interest in tech giants like NVIDIA, Broadcom, and Alphabet, and transitional events like NVIDIA's CAO change and AParadise's Nasdaq-to-NYSE shift post-merger. Period-over-period trends show YoY improvements in EBITDA (Verizon +6.7%), FFO (Sun +11.1% per share), and EPS (Verizon +7.6%), but QoQ declines in net income (Citizens -11.6%) and rising debt loads (Verizon unsecured debt +8.7% QoQ to $142.5B). Guidance raises in Verizon (EPS to $4.95-$4.99, +5-6% YoY) and Sun (Core FFO +60 bps) signal confidence amid flat wireless outlooks, while 13Fs highlight put exposure on HPE (Portman $79M) as a bearish outlier. Capital allocation leans toward debt reduction (Verizon halving Frontier debt) and dividends (Citizens $0.105/share), with M&A activity limited to Sun's $27.6M acquisitions and AParadise merger. Overall, bullish operational momentum in core tech/telecom contrasts with leverage risks, positioning selective longs in guidance-upgraders amid institutional tech conviction.

4 high priority 9 medium 13 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 27, 2026

Across 19 SEC filings from NASDAQ-100 related entities, key themes include robust operational improvements in telecom (Verizon Q1 revenue +2.9% YoY, EBITDA +6.7%) and REITs (Sun Communities Same Property NOI +6.3% YoY), contrasted by mixed mining results (Liberty Star net loss $1.24M FY2026 vs prior income, Metals Royalty continuing ops loss widened to $6.84M) and neutral proxy-heavy activity signaling governance focus ahead of June annual meetings. Biotech standout with Intellia Therapeutics' Phase 3 HAELO trial success (87% attack rate reduction, BLA rolling submission H2 2026). Period-over-period trends show 4/7 earnings filings with YoY net income/loss improvements (e.g., Verizon +3.3%, Sun -80% loss narrowing), but debt burdens persist (Verizon unsecured debt +$11.4B QoQ) and occupancy dips in REITs (-20 bps YoY). Guidance raises in telecom/REITs (Verizon Adj EPS $4.95-4.99, Sun Core FFO $6.87-7.07) build 2026 optimism, while SPAC delistings (AParadise to NYSE May 8) and equity registrations (Tesla 304M shares for Musk) flag dilution/transition risks. Portfolio-level: Positive FCF/cash flow in 3/4 reporters (Verizon +4% YoY FCF), proxy approvals likely to pass unanimously, positioning for M&A/capital events.

9 high priority 10 medium 19 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 27, 2026

Across 50 filings spanning diverse sectors mislabeled under S&P 500 Financials, proxy season dominates with 20+ annual/special meetings clustered in May-June 2026, featuring director elections, equity plan expansions (e.g., RYTHM +115k shares, Velo3D +2.86M), and auditor ratifications amid neutral sentiment. M&A activity surges with Sun Pharma's $11.75B acquisition of Organon at $14/share (103% premium, close early 2027) and Cintas' merger with UniFirst (UNF shareholders get $155 cash + 0.772 CTAS shares), signaling strategic consolidation. Reported financials show mixed trends: revenues grew +3.5% YoY at Domino's and +13% net interest at Ladder Capital, but net income plunged -78% at Ladder, -6.6% at Domino's, -19.7% rev/-net income flip at Heartland Express, 100% rev drop at Alternus, and loss widening at Seaport Therapeutics (R&D +164%). Capital allocation leans positive with Domino's $1B buyback + $1.99 div (June 30), Heartland $0.02 div, and New ERA's $50M debt prepay; institutional 13Fs (10+ filings) confirm mega-cap tech overweight (Apple, Amazon top holdings). Risks emerge from litigation ($70M Oppenheimer settlement), restatements (Driven Brands), cyber incidents (Medtronic), and dilution (Tesla 304M S-8 shares for Musk). Overall, actionable alpha in merger arb (Organon), buybacks (Domino's), and debt cleanups amid proxy-driven governance catalysts.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 27, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Staples stream (broadly including adjacent sectors like beverages and REITs), proxy statements dominate (neutral sentiment, 20+ filings) signaling active AGM season in May-June 2026, while 13F-HR reports (10+ filings) show stable institutional portfolios heavily weighted in tech/ETFs with no major shifts. Q1 2026 earnings reveal robust YoY revenue growth averaging 30-50% (e.g., Celestica +53%, Amkor +27%, Steel Dynamics +19%) and net income surges (LendingClub +342%, Brixmor +83%), but QoQ declines (Amkor sales -11%, cash dips) yield mixed sentiment in 8/12 financial reporters. Capital allocation trends bullish with buybacks (Amkor $300M new auth, Steel $115M Q1, Lakeland $21M remaining), dividends (Brixmor $0.3075 Q, Mobile Infra monthly prefs), and dispositions (Brixmor $107.9M). Consumer Staples highlights include CCEP's 1.3M share buyback and Krispy Kreme's volatile exec comp (CEO +47% YoY but no incentives). M&A activity (Aerkomm merger valued NT$651M, Cleco equity sale pending regs) and pivots (Envirotech to drones/AI) add dynamism; implications favor selective longs in high-growth reporters amid proxy catalysts, but flag risks in zero-rev firms like Alternus.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 27, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly encompassing adjacent sectors like financials, pharma, and energy due to filing mix), Q1 2026 earnings from 7 regional banks reveal resilient net income growth averaging 18% YoY (e.g., Northwest +16%, Avidbank +67% YoY) driven by NIM expansion (+20-70bps avg) and loan growth (10-18% YoY), though asset quality deteriorates with classified/NPAs rising. Revenue trends mixed: 6/10 earnings reporters show +2.9-6.9% YoY growth (Verizon, BBBY first in 19q), but customer bases decline (BBBY -17%). Positive catalysts include BioMarin's $4.8B Amicus acquisition, Verizon's raised FY2026 guidance (adj EPS +5-6%, FCF $21.5B+), and pharma product launches/appointments; capital allocation favors dividends ($0.05-0.20/share) and buybacks (Northwest $50M new program). 25+ 13F-HR filings highlight institutional tilt to passive ETFs (S&P500, total market ~20-30% allocations avg) signaling broad stability. Proxy season ramps with 15+ AGMs in May-June, neutral sentiment overall but bullish on financial recovery. Portfolio implication: overweight banks with NIM tailwinds, monitor industrials like Stanley Black & Decker (AGM wins) for tools/mfg cycle.

13 high priority 37 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 27, 2026

The 12 filings for the USA S&P 500 Energy stream reveal limited core energy activity, headlined by Kinder Morgan's upcoming Barclays conference on May 5, 2026, amid a broader surge in cross-sector M&A announcements spanning biotech (XOMA/Ligand acquisition at 14% premium, Generation Bio tender) and real estate (Real Brokerage's $880M RE/MAX deal with $30M synergies). COPT Defense Properties stands out with robust Q1 2026 results: net income +10.8% YoY to $40.1M, NOI +7.2% YoY to $115.2M, FFO/share +6.2% to $0.69, and stable 6.1x net debt/EBITDA. Ligand raised 2026 guidance post-XOMA deal to revenue $270-310M (up from $245-285M), royalties $225-250M (up from $200-225M), and adj EPS $8.50-9.50 (up from $8.00-9.00), signaling M&A-driven optimism. Rochester Wealth's 13F shows modest energy exposure with Chevron ($1.66M) and Exxon ($1.05M) amid ETF-heavy portfolio. Positive/mixed sentiments dominate (9/12), with forward catalysts in H2 2026 deal closes; however, SPAC delistings introduce short-term volatility. Portfolio-level trends highlight accretive M&A and stable leverage, contrasting quiet energy ops beyond KMI visibility event.

7 high priority 5 medium 12 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 27, 2026

Across 50 SEC filings from April 27, 2026, primarily involving non-DJ30 names but with Verizon (DJ30) as a standout, overarching themes include peak proxy season with 20+ AGMs scheduled May-June 2026, positive biotech clinical readouts, M&A activity, and 13F snapshots revealing institutional mega-cap tech bias (e.g., AAPL top holding in 12/15 13Fs). Period-over-period trends show telecom resilience (Verizon Q1 revenue +2.9% YoY, EBITDA +6.7% YoY, EPS +7.6% YoY) contrasting credit/fintech pressures (Golub NAV -4.0% QoQ, Qfin net income -4.4% YoY, Hemab losses +31% YoY to $63.9M); operational metrics highlight Verizon's record postpaid adds (+55k Q1) and Easterly's Core FFO $0.77/share. Critical developments: Verizon raised FY2026 Adjusted EPS guidance to $4.95-$4.99 (+5-6% YoY), RE/MAX M&A forming 180k-agent platform, Veradermics Phase 2/3 hair loss trial success (30-33 hairs/cm² vs placebo 7.3, p<0.0001). Portfolio-level patterns indicate bullish biotech/health catalysts (5/7 positive sentiment), mixed credit (NAV compression amid stable leverage), and heavy tech allocations in 13Fs (~20-30% AAPL/AMZN/GOOG across filers) signaling conviction in DJ30 tech giants like AAPL. Capital allocation favors dividends/FCF (Verizon FCF +4% YoY to $3.8B, Solstice $0.075/share div, Easterly $0.45/share), with low buybacks but SPAC IPOs and shelf registrations for fundraising.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 27, 2026

Across 50 SEC filings from the S&P 500 Consumer Discretionary stream (broadly encompassing retail, auto, and adjacent sectors amid mixed inclusions), Q1 2026 earnings reveal resilient net income growth in financials and select industrials (e.g., Lakeland +32% YoY, Bank of Hawaii +30.6% YoY) with NIM expansions averaging +7bps across reporting banks, offsetting margin pressures elsewhere; revenue trends mixed with outliers like Solaris +55% QoQ but Kforce flat YoY. M&A momentum accelerates with BioMarin $4.8B Amicus close, multiple bank mergers (Flushing/OceanFirst by June 1) securing approvals, and Tesla registering 304M shares for Musk's 2018 award signaling milestone achievement. 13F portfolios (15+ filings) show extreme concentration in mega-tech (AAPL, MSFT, AMZN, NVDA topping most), underscoring conviction amid Consumer Discretionary volatility. Capital allocation favors returns (Kforce $11.7M repos + $6.8M divs; Solaris $0.12 div), but cash burn widens losses in biotech/energy (Fulcrum -$18.9M). Guidance mostly raised/issued (Solaris Q2 EBITDA $83-93M up from prior), building Q2 catalysts; sentiment mixed (18/50), with portfolio-level margin stability but deposit/loan softness in banks.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 27, 2026

Across 50 SEC filings from the USA S&P 500 Healthcare stream (though heavily skewed to financials/banks with limited pure healthcare), key themes include mixed Q1 2026 results with YoY net income surges (Lakeland Financial +32% to $26.5M, Cincinnati Financial swing from -$90M to +$274M, HBT adjusted +12.4% QoQ) offset by QoQ declines and merger costs, accelerating M&A with full regulatory nods for OceanFirst/Flushing (close by June 1) and HBT/CNB completed adding $1.8B assets. Healthcare highlights feature Sagimet Biosciences' strong partner Phase 3 acne data (33.2% success vs 14.6% placebo, US Ph3 2H26), Medtronic's contained cyber incident (no material impact expected), and strong proxy approvals at Pfizer/Cigna (94-98% director support). Capital allocation trends bullish with share repurchases ramping (Waterstone +2M shares auth to 2.1M avail, FB Financial $175M renewed thru 2027, Lakeland $21.2M remaining, Cincinnati $179M Q1) and dividend hikes (Cincinnati +8% to $0.94/share). Forward-looking catalysts cluster in June (mergers, AGMs), while 13F filings reveal broad ETF/stock holdings neutral. Portfolio-level, financials drive consolidation/returns themes, healthcare shows biotech promise amid cyber/governance risks; actionable now: buy merger arb plays, monitor deposit trends.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 24, 2026

Across 27 filings in the USA S&P 500 Technology intelligence stream, proxy season dominates with 15+ DEF 14A/DEFA14A disclosures signaling upcoming AGMs in May-June 2026 as key catalysts for governance votes, equity plan expansions, and say-on-pay approvals (e.g., Acadia May 29, Block June 16). Q1 2026 financials show stark divergence: Texas Instruments (TXN) delivered blowout growth with revenue +18.6% YoY to $4.8B, net income +31% to $1.5B, and op cash flow +79% to $1.5B, contrasting Charter Communications' -1% YoY revenue decline to $13.6B amid video revenue -9.1%. Institutional 13F filings (Muzinich, Semus, United Community Bank, Squire) reveal persistent conviction in mega-cap tech leaders like AAPL ($34M-$4B positions), NVDA ($7.5M+), MSFT, AMZN, underscoring portfolio concentration in growth tech. Capital allocation remains shareholder-friendly with TXN's $1.3B Q1 dividends, FHLB's $75M special dividend, Genco's record $0.50/share, and Charter's buybacks boosting EPS +7.9% despite NI drop. Mixed sentiment prevails (9 mixed, 13 neutral, 3 positive), with no major insider selling but positive exec comp beats (Immunome bonuses 145-150% of target). Forward catalysts include Altimmune's Phase 3 MASH trial funding from $211M raise and Genco's proxy battle. Overall, tech sector shows resilient institutional demand and semi strength amid broader mixed trends, favoring longs in outperformers like TXN.

13 high priority 14 medium 27 total filings